Therapeutic compositions

Abstract

The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.

1 . A method for the treatment of hypertension, pulmonary hypertension or pulmonary arterial hypertension, comprising administering simultaneously, separately or over a period of time, to a patient in need thereof, an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       in free or pharmaceutically acceptable salt form, and at least one compound having PDE5-inhibitory properties, in free or pharmaceutically acceptable salt form. 
     
     
         2 . The method according to  claim 1 , wherein the compound of formula (I) and the compound having PDE5-inhibitory properties are administered simultaneously. 
     
     
         3 . The method according to  claim 1 , wherein the compound of formula (I) and the compound having PDE5-inhibitory properties are administered separately. 
     
     
         4 . The method according to  claim 1 , wherein the compound of formula (I) and the compound having PDE5-inhibitory properties are administered over a period of time. 
     
     
         5 . The method according to  claim 4 , wherein the administration of the compound of formula (I) will be alternated with the administration of a compound having PDE5-inhibitory properties, and the interval between such administration will not exceed two or three days. 
     
     
         6 . The method according to  claim 5 , wherein said administration will not exceed one day. 
     
     
         7 . The method according to  claim 1 , wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil. 
     
     
         8 . The method according to  claim 1 , wherein the compound having PDE5-inhibitory properties is sildenafil. 
     
     
         9 . The method according to  claim 1 , wherein the compound having PDE5-inhibitory properties is tadalafil. 
     
     
         10 . The method according to  claim 1 , wherein the disease intended to be treated is pulmonary hypertension. 
     
     
         11 . The method according to  claim 1 , wherein the disease intended to be treated is pulmonary arterial hypertension. 
     
     
         12 . A method for the treatment of pulmonary arterial hypertension, comprising administering to a patient in need thereof, simultaneously, an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       in free or pharmaceutically acceptable salt form, and at least one of sildenafil or tadalafil, in free or pharmaceutically acceptable salt form. 
     
     
         13 . A method for the treatment of pulmonary arterial hypertension, comprising administering over a period of time, to a patient in need thereof, an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       in free or pharmaceutically acceptable salt form, and at least one of sildenafil or tadalafil, in free or pharmaceutically acceptable salt form. 
     
     
         14 . A method for the treatment of pulmonary arterial hypertension, comprising administering to a patient in need thereof, separately, an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
       
       in free or pharmaceutically acceptable salt form, and at least one of sildenafil or tadalafil, in free or pharmaceutically acceptable salt form.